Patents by Inventor Nikolai A. Kley

Nikolai A. Kley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1 and PD-L1 binding agents
    Patent number: 11498966
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: November 15, 2022
    Assignees: Orionis Biosciences Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • CLEC9A BINDING AGENTS
    Publication number: 20220356253
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: April 5, 2021
    Publication date: November 10, 2022
    Inventors: Jan TAVERNIER, Nikolai KLEY, Anje CAUWELS, Sarah GERLO
  • FIBROBLAST ACTIVATION PROTEIN BINDING AGENTS AND USE THEREOF
    Publication number: 20220332844
    Abstract: The present invention relates, in part, to agents, chimeric proteins and protein complexes that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents, chimeric proteins and protein complexes and their use in the treatment of various diseases.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 20, 2022
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU
  • Therapeutic interferon alpha 1 proteins
    Patent number: 11440943
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: September 13, 2022
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Erik Depla, Lennart Zabeau, Jan Tavernier
  • TARGETED CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20220281992
    Abstract: The present invention relates, in part, to chimeric proteins comprising at least one targeting moiety that recognizes and binds SIRP1? and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Application
    Filed: May 16, 2022
    Publication date: September 8, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER
  • COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXES
    Publication number: 20220249609
    Abstract: The present invention relates, in part, to chimeric protein or chimeric protein complex comprising a CD13 targeting moiety and a signaling agent (e.g., without limitation TNF or IFN-?) and methods of treatment using such compositions.
    Type: Application
    Filed: June 18, 2020
    Publication date: August 11, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER, Leander HUYGHE
  • Targeted chimeric proteins and uses thereof
    Patent number: 11384154
    Abstract: The present invention relates, in part, to chimeric proteins comprising at least one targeting moiety that recognizes and binds SIRP1? and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: July 12, 2022
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier
  • FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L)-BASED CHIMERIC PROTEINS
    Publication number: 20220185857
    Abstract: FMS-like tyrosine kinase 3L (FLT3L) fused to human cytokines, which find use in, e.g., cancer treatments, is described.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER, Alexander VAN PARYS
  • CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3)
    Publication number: 20220177550
    Abstract: Chimeric proteins or chimeric protein complexes, such as an Fc-based chimeric protein complexes directed to FMS-like tyrosine kinase 3 (FLT3), optionally composed of a FMS-like tyrosine kinase 3L (FLT3L) domain and human cytokines, which find use in, e.g., cancer treatments, are described.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • CD8 BINDING AGENTS
    Publication number: 20220177586
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 9, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Sarah GERLO
  • CLEC9A-BASED CHIMERIC PROTEIN COMPLEXES
    Publication number: 20220153801
    Abstract: The present invention relates, in part, to chimeric protein complexes including an anti-Clec9A targeting moiety, a modified Fc domain, and a modified human IFN? and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric protein complexes and their use in the treatment of various diseases.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 19, 2022
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • SIRP1A TARGETED CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20220119519
    Abstract: The present invention relates, in part, to agents that bind SIRP1? and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the SIRP1? targeting moiety and their use in the treatment of various diseases.
    Type: Application
    Filed: August 8, 2019
    Publication date: April 21, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER
  • MODULATION OF DENDRITIC CELL LINEAGES
    Publication number: 20220119472
    Abstract: The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 21, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Lennart ZABEAU, Erik DEPLA
  • TARGETED MUTANT INTERFERON-BETA AND USES THEREOF
    Publication number: 20220089668
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 24, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER, Frank PEELMAN
  • Targeted mutant interferon-beta and uses thereof
    Patent number: 11236141
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: February 1, 2022
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman
  • CD8 binding agents
    Patent number: 11236166
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 1, 2022
    Assignees: Orionis Biosciences BV, VIB VZW, UNIVERSITEIT GENT
    Inventors: Nikolai Kley, Jan Tavernier, Anje Cauwels, Sarah Gerlo
  • PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP
    Publication number: 20220026439
    Abstract: The present invention relates to the use of a particle, including a virus-like particle (VLP), for the discovery and analysis of protein-protein interactions that are modulated by small molecules.
    Type: Application
    Filed: December 19, 2019
    Publication date: January 27, 2022
    Inventors: Nikolai KLEY, Samuel LIEVENS, Riccardo SABATINI
  • TARGETED MUTANT INTERFERON-GAMMA AND USES THEREOF
    Publication number: 20210403525
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Application
    Filed: July 2, 2021
    Publication date: December 30, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Frank PEELMAN, Lennart ZABEAU
  • TARGETED THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20210388088
    Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 16, 2021
    Inventors: Jan TAVERNIER, Nikolai KLEY
  • Targeted mutant interferon-gamma and uses thereof
    Patent number: 11084859
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 10, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau